home / stock / cstl / cstl news


CSTL News and Press, Castle Biosciences Inc. From 02/05/26

Stock Information

Company Name: Castle Biosciences Inc.
Stock Symbol: CSTL
Market: NASDAQ
Website: castlebiosciences.com

Menu

CSTL CSTL Quote CSTL Short CSTL News CSTL Articles CSTL Message Board
Get CSTL Alerts

News, Short Squeeze, Breakout and More Instantly...

CSTL - Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the clo...

CSTL - Wasatch Micro Cap Fund Q4 2025 Performance Review

2026-02-04 08:35:00 ET ... Read the full article on Seeking Alpha For further details see: Wasatch Micro Cap Fund Q4 2025 Performance Review

CSTL - AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit

2026-02-03 17:20:03 ET On Feb. 2, 2026, AIGH Capital Management LLC reported a complete sale of its Lumen Technologies (NYSE:LUMN) stake, with an estimated transaction value of $15.61 million based on quarterly average pricing. According to an SEC filing dated Feb. 2, 2026, ...

CSTL - CSTL Price Target Alert: $50.00. Issued by KeyBanc

2026-01-29 16:04:38 ET Paul Knight from KeyBanc issued a price target of $50.00 for CSTL on 2026-01-29 20:40:30. The adjusted price target was set to $50.00. At the time of the announcement, CSTL was trading at $39.16. The overall price target consensus is at $49.75 with...

CSTL - Overweight Recommendation Issued On CSTL By KeyBanc

2026-01-29 15:15:03 ET KeyBanc analyst issues OVERWEIGHT recommendation for CSTL on January 29, 2026 08:40PM ET. The previous analyst recommendation was Overweight. CSTL was trading at $39.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

CSTL - Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results

2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Year-end 2025 cash, cash equivalents a...

CSTL - CSTL Price Target Alert: $50.00. Issued by Canaccord Genuity

2025-12-22 07:06:10 ET from Canaccord Genuity issued a price target of $50.00 for CSTL on 2025-12-22 11:54:26. The adjusted price target was set to $50.00. At the time of the announcement, CSTL was trading at $39.44. The overall price target consensus is at $50.00 with h...

CSTL - Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-b...

CSTL - Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new systematic review and meta-analysis (SRMA) demonstrating that the TissueCypher &#x...

CSTL - Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cuta...

Previous 10 Next 10